Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®)
about
Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections.Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.Impact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine - a pilot studyHPV vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against HPV-positive tumour cellsEfficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial.Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteinsCharacteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclassesA comparative study of two different assay kits for the detection of secreted alkaline phosphatase in HPV antibody neutralization assays.Cancer prevention in HIV-infected populations.The papillomavirus major capsid protein L1.Comparison of antibody responses to human papillomavirus vaccination as measured by three assays.Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities.Development of neutralizing monoclonal antibodies for oncogenic human papillomavirus types 31, 33, 45, 52, and 58Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs.Prophylactic HPV vaccination: past, present, and future.JC polyomavirus mutants escape antibody-mediated neutralization.Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study.Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development.Explanations for the high potency of HPV prophylactic vaccines.Comparative Cost-Effectiveness Analysis of Two Different Two-Dose Human Papillomavirus Vaccines in Malaysia
P2860
Q30353668-5CA0FEA5-217B-4830-9D02-B00A38E8DD29Q33723312-007DFE62-CDDA-474B-9234-0A0A9C775354Q33929216-71906C4B-89D8-44AE-9699-AFF6F6D1ADA6Q34011491-E1FA0FCF-5A69-4760-B2F1-1B69AEA836ACQ34199560-B1F0BD92-A267-4F77-841A-CD695B75E72CQ34492140-FDAF7A2E-0A0E-4474-B38E-1D956A13A8ABQ34994905-C0B8E1A7-220B-4A68-A4FC-261509BA1D5FQ35887709-7822AA49-95A2-4593-A362-BC1A232CA969Q36680086-248035BA-9FEA-4853-9E28-4F6589673309Q37198519-254B9770-70B9-4C8A-8E8C-9F5813EFFC58Q37466826-E171AE91-4F2D-424B-89F4-D9342B118A30Q37671423-AEFD5206-A8B9-4AA1-A6FA-4448DBC791A9Q37712837-8EBEEB40-AB02-41A0-8DB0-11ACA15F9AA4Q38255277-00E54558-4260-4BC7-B9B2-C1D5B714788FQ38597567-CA48EDD6-E6D0-4C13-9D4F-CF9FA73E67C7Q40984700-4A456073-955F-4EF6-9329-47C6A01D03C8Q42260852-55503548-B3DF-424E-8247-9C3FA3D50ACDQ47549756-7ACD35FA-B905-47CB-8E52-73184F2CFEE5Q47554977-8E4154D7-77DB-4314-A1C4-D091E3FB16D2Q55540751-96520F93-7B2D-4527-88D1-274E77A1278B
P2860
Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®)
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Kinetic and HPV infection effe ...... sponses induced by Cervarix(®)
@ast
Kinetic and HPV infection effe ...... sponses induced by Cervarix(®)
@en
type
label
Kinetic and HPV infection effe ...... sponses induced by Cervarix(®)
@ast
Kinetic and HPV infection effe ...... sponses induced by Cervarix(®)
@en
prefLabel
Kinetic and HPV infection effe ...... sponses induced by Cervarix(®)
@ast
Kinetic and HPV infection effe ...... sponses induced by Cervarix(®)
@en
P2093
P2860
P1433
P1476
Kinetic and HPV infection effe ...... sponses induced by Cervarix(®)
@en
P2093
Carolina Porras
Douglas R Lowy
John T Schiller
Kerri J Penrose
Ligia A Pinto
Rolando Herrero
Troy J Kemp
Yuanji Pan
P2860
P304
P356
10.1016/J.VACCINE.2012.10.067
P407
P577
2012-10-31T00:00:00Z